Mission Therapeutics forges ahead with Phase II study for DUB inhibitor
A Phase II clinical trial treating 160 acute kidney injury patients with MTX652 is expected to be initiated in Q1 2024.
A Phase II clinical trial treating 160 acute kidney injury patients with MTX652 is expected to be initiated in Q1 2024.
What's Your Reaction?
